Disc Medicine Q1 net loss $26.9M; bitopertin AURORA trial misses primary endpoint, but shows secondary benefits

Disc Medicine, Inc.

2024-Q1 EPS reported -$1.09

Cash and cash equivalents $342.6M at March 31, 2024; provides runway well into 2026.
Net loss $26.9M in Q1 2024 vs. $22.8M in Q1 2023; R&D expense rose to $23.7M from $20.2M.
Bitopertin AURORA phase 2 in EPP: significant PPIX reduction; missed primary endpoint (light tolerance) due to placebo benefit; 60mg dose showed significant reduction in phototoxic pain reactions.
Received FDA Rare Pediatric Disease Designation for bitopertin in EPP in May 2024.
On track to present additional AURORA/BEACON data, initial DISC-3405 SAD data, and updated DISC-0974 MF data in Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Disc Medicine, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $26.9 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $26.9 million
Result: reported results

Exact text from the filing

Disc Medicine, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-134796

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.